Every Form 4 that BioNexus Gene Lab Corp (BGLC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BGLC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BGLC filings page.
Tan Lee Su-Leng reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp reported that Chief Executive Officer and director Tan Lee Su-Leng, a more than 10% shareholder, received a fully vested stock award. The award consists of 338,709 common shares with no par value, granted on August 13, 2026 under the company’s 2025 Equity Incentive Plan.
The shares were granted for completed services, with no cash consideration, and were valued for plan purposes at $1.55 per share, based on the Nasdaq closing price on August 12, 2026. Following this grant, the reporting person directly holds 338,709 common shares.
Yap Chee Keong reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp director Yap Chee Keong received a fully vested stock award of 32,258 Common Shares on August 13, 2026. The award was granted for completed services under the 2025 Equity Incentive Plan, for no cash consideration, and is held as a direct ownership position of 32,258 shares. For plan purposes, the award was valued at $1.55 per share, equal to the Nasdaq closing price on August 12, 2026.
Bin Abdul Hamid Muhammad Azrul reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul received a fully vested stock award of 32,258 Common Shares on August 13, 2026. The award was granted under the company’s 2025 Equity Incentive Plan for completed services, for no cash consideration, and was valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this grant, his direct holdings total 32,258 shares.
Chong Set Fui reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp’s Chief Financial Officer, Chong Set Fui, received a fully vested stock-based award of 96,774 common shares on August 13, 2026. The award was granted under the company’s 2025 Equity Incentive Plan for completed services, with no cash consideration, and was valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this grant, Chong Set Fui directly holds 96,774 common shares.
Low Jook Yuen reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp director Low Jook Yuen received an equity compensation grant of 16,129 shares of common stock on August 13, 2026. The fully vested Other Stock-Based Award was granted for completed services under the company’s 2025 Equity Incentive Plan, for no cash consideration, and valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this award, Low Jook Yuen holds 17,390 shares of BioNexus Gene Lab Corp common stock directly.